Atypical Hemolytic Uremic Syndrome - 18 Studies Found
Completed |
: Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS : Atypical Hemolytic Uremic Syndrome : 2009-02-13 : Drug: Eculizumab All patients received open-label eculizumab administered intravenously on the following |
Completed |
: Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS : Atypical Hemolytic Uremic Syndrome : 2009-02-13 : Drug: Eculizumab All patients received open-label eculizumab administered intravenously on the following |
Completed |
: Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS : Atypical Hemolytic Uremic Syndrome : 2009-02-12 : Drug: eculizumab All patients received open-label eculizumab administered intravenously on the following |
Completed |
: The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS) : Atypical Hemolytic Uremic Syndrome (aHUS) : 2012-12-04 : Drug: Eculizumab |
Recruiting |
: Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS) : Atypical Hemolytic Uremic Syndrome (aHUS) : 2016-10-25 : Biological: ALXN1210 Single loading dose on Day 1, followe |
Completed |
: To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients : ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) : 2012-12-04 |
Enrolling by invitation |
: Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment : Atypical Hemolytic Uremic Syndrome : 2015-11-24 : Other: Clinical assessments and laboratory tests. Clinical assessments and laboratory tests required at |
Enrolling by invitation |
: The Role of Microparticles as a Biomarker :
|